Provenance Record

Clean, well-structured News piece with appropriate clinical-trial caution. Overview/What We Know/Background/What We Don't Know structure separates company-reported data from independent reporting, and the 'What We Don't Know' section properly notes the Week 52 figures are single-arm rates (n=396) not directly comparable to the Week 16 placebo-adjusted deltas. 801 words, within the News 400-1200 range.

All 4 snapshots read from disk and verified (all status 200). source-0.html.gz (MoonLake/GlobeNewswire press release): confirms every clinical specific per Rule 9 — 67.2% HiSCR75, 33.1% HiSCR100, 26.0% IHS4-100 (all n=396), VELA-1 68.3%/31.2% and VELA-2 66.0%/35.1% breakouts, 838 patients, 120mg Q4W (once every four weeks), BLA expected end of September 2026, HiSQOL -15.3 (VELA-1)/-14.8 (VELA-2), 46.5% pain reduction (>=3-point NRS), 2% prevalence, three times more females, 2 million U.S. patients 2016-2023, IL-17A/IL-17F Nanobody, and Week 16 deltas (VELA-1 17% p<0.001; VELA-2 9% p=0.053). Both executive quotes verbatim with correct titles: Dr. Jorge Santos da Silva, Founder and Chief Executive Officer; Prof. Kristian Reich, Founder and Chief Scientific Officer. source-1 (StockTitan) and source-2 (BioSpace) corroborate the breakout figures attributed to StockTitan. source-3 (BioPharma Dive): confirms ~80% share drop on Sept. 29, 2025, VELA-1 ~35% vs ~18% placebo at four months, VELA-2 failed its main objective (company blamed 'higher than expected' placebo response), 'uncompetitive' with Bimzelx framing, and AbbVie's Humira / UCB's Bimzelx / Novartis' Cosentyx named.

All numbers, dates, names, and quotes trace to cited snapshots. The 'best-in-class' descriptor in the press release ('best-in-class and best-in-disease profile') is correctly handled as company framing — the article explicitly flags it in 'What We Don't Know' as a competitive claim that cannot be verified from the VELA trials, which had no active comparator. Generic drug names added in parentheses (bimekizumab, adalimumab, secukinumab) are standard, non-controversial generics for the named brands and not in dispute.

APPROVE. Rule 9 satisfied: every clinical specific is cited to the MoonLake release that carries it; the Week 16 mixed-readout context is cited to BioPharma Dive; both executive quotes are verbatim with correct titles; and 'best-in-class' is flagged as company framing rather than asserted as fact. No corrections needed.